News|Videos|October 17, 2023
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB
Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Advertisement
Please see full
Sponsored by AbbVie US Medical Affairs
Episodes in this series
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Advertisement
Related to this article
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
4
FDA grants 510(k) clearance to OpenFlo urinary catheter
5